• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Connect Biopharma Advances Seabreeze STAT Phase 2 Post-Interim

    GLOBENEWSWIRE

    Connect Bio Reports 2025 Financials And Business Update

    GLOBENEWSWIRE

    Rademikibart Show Best-in-Class Potential in Ph3 AD Dermatitis

    GLOBENEWSWIRE

    Connect Bio Secures $20.2M In Private Placement Financing

    GLOBENEWSWIRE

    Connect Bio: Phase 1 (IV) Rademikibart Data In Asthma, COPD

    GLOBENEWSWIRE

    Connect Bio To Present At Oppenheimer Healthcare Conference

    GLOBENEWSWIRE

    Connect Biopharma Highlights Rademikibart MOA Data, Sets 2026

    GLOBENEWSWIRE

    Connect Biopharma to join BTIG Virtual Biotechnology Conference

    GLOBENEWSWIRE

    Connect Biopharma presents Rademikibart data at EAACI 2025 Congre

    GLOBENEWSWIRE

    Connect Biopharma Reports Q1 2025 Results and Business Update

    GLOBENEWSWIRE

    Connect Bio`s Positive Type C Meeting with FDA for Rademikibart

    GLOBENEWSWIRE

    Connect Biopharma Announces Positive Data from Global Ph 2 Trial

    GLOBENEWSWIRE

    Connect Biopharma To Participate In Cantor Conference

    GLOBENEWSWIRE

    Connect Bio Presents Positive Rademikibart Phase 2b Asthma At ATS

    GLOBENEWSWIRE

    Connect Bio Announces Positive Rademikibart Global Phase 2b Topline Results

    GLOBENEWSWIRE

    Connect Biopharma to Announce Top-Line Data from Phase 2b Trial of Rademikibart

    GLOBENEWSWIRE

    Connect Biopharma Announces Data from the China Pivotal Trial of Rademikibart

    GLOBENEWSWIRE

    Connect Biopharma to Announce Data from the China Pivotal Trial of Rademikibart

    GLOBENEWSWIRE

    Connect Biopharma CBP-201 Study Showed Rapid Relief of Patient Symptoms

    BUSINESSWIRE

    Connect CBP-201 Atopic Dermatitis Ph2b Showed Improvement Across Body Regions

    BUSINESSWIRE

    Connect CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.